Literature DB >> 2431056

Interleukin 1 releases histamine from human basophils and mast cells in vitro.

N Subramanian, M A Bray.   

Abstract

Interleukin (IL 1) preparations from five different sources (human monocyte, LPS-stimulated, purified IL 1 from two different laboratories) and human recombinant IL 1 (HrIL 1) were shown to be capable of directly inducing histamine (HA) release from human basophils (10 to 50% of total cellular HA, depending on the source of IL 1). The release was not due to the medium, pyrogens, or other contaminants. Il 1-induced HA release was dose dependent between 1 to 100 U/ml of IL 1 and 1 to 15 ng/ml of HrIL 1 and was rapid, with a peak release at 15 min. HA release induced by IL 1 was blocked completely by preexposure of cells to IL 1 but was not affected by prechallenge with anti-IgE. Also, preincubation of IL 1 with anti-IL 1 antibody abolished the HA-releasing activity. IL 1-induced HA release was also observed in preparations of human adenoidal mast cells. Our data indicate that it is unlikely that the HA release induced by IL 1 is due to a contamination with HA-releasing factor. This effect of IL 1 provides a mechanism for non-IgE-related local HA release and raises the possibility of a link between cellular immunity and immediate hypersensitivity of potential importance for the pathology of immuno/inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2431056

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

Authors:  Amrita Ahluwalia; Paul Foster; Ramona S Scotland; Peter G McLean; Anthony Mathur; Mauro Perretti; Salvador Moncada; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

2.  The determination of histamine in challenged human leukocyte preparations by high-performance liquid chromatography.

Authors:  L Leino; A Juhakoski; L Lauren
Journal:  Agents Actions       Date:  1990-11

3.  Interleukin-1 beta increases airway epithelial cell mitogenesis partly by stimulating endothelin-1 production.

Authors:  C G Murlas; A C Sharma; A Gulati; F Najmabadi
Journal:  Lung       Date:  1997       Impact factor: 2.584

4.  Chronic urticaria--a frustrating but increasingly understandable disorder.

Authors:  S I Wasserman
Journal:  West J Med       Date:  1990-03

5.  Potentiation of histamine release from human leucocytes by PAF.

Authors:  R Louis; T Bury; J L Corhay; M F Radermecker
Journal:  Agents Actions       Date:  1994-03

Review 6.  Mast cell polymorphisms. Present concepts, future directions.

Authors:  D Befus; H Fujimaki; T D Lee; M Swieter
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

7.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 8.  Stress physiology in marine mammals: how well do they fit the terrestrial model?

Authors:  Shannon Atkinson; Daniel Crocker; Dorian Houser; Kendall Mashburn
Journal:  J Comp Physiol B       Date:  2015-04-26       Impact factor: 2.200

Review 9.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

10.  Phosphatidylcholine-specific phospholipase D-derived 1,2-diacylglycerol does not initiate protein kinase C activation in the RBL 2H3 mast-cell line.

Authors:  P Lin; W J Fung; A M Gilfillan
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.